TY - JOUR AU - Göbel, Andy AU - Zinna, Valentina M. AU - Dell’Endice, Stefania AU - Jaschke, Nikolai AU - Kuhlmann, Jan Dominik AU - Wimberger, Pauline AU - Rachner, Tilman D. PY - 2020 DA - 2020/07/29 TI - Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer JO - BMC Cancer SP - 703 VL - 20 IS - 1 AB - Ovarian cancer remains the most fatal gynecological malignancy. Current therapeutic options are limited due to late diagnosis in the majority of the cases, metastatic spread to the peritoneal cavity and the onset of chemo-resistance. Thus, novel therapeutic approaches are required. Statins and amino-bisphosphonates are inhibitors of the mevalonate pathway, which is a fundamental pathway of cellular metabolism, essential for cholesterol production and posttranslational protein farnesylation and geranylgeranylation. While this pathway has emerged as a promising treatment target in several human malignancies, its potential as a therapeutic approach in ovarian cancer is still not fully understood. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-020-07164-x DO - 10.1186/s12885-020-07164-x ID - Göbel2020 ER -